TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Trial of Brief Intervention for Problem Drinking and Partner Violence
Brief Summary: This study is a randomized controlled trial of a brief intervention for women Emergency Department patients with involvement in both Intimate Partner Violence (IPV) and problem drinking (defined as the full spectrum of hazardous, harmful, or dependent drinking). The study is designed to explore the effectiveness of a low-intensity, gender-sensitive brief motivational intervention, delivered by social workers in the Emergency Department setting, in decreasing IPV and episodes of heavy drinking and increasing rates of follow-up with resources. Social work graduate students and/or staff will be trained to provide brief motivational enhancement therapy (MET) intervention for decreasing heavy drinking and IPV-related injury in women Emergency Department patients.


Options:
A: Arm Label: Online intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Online intervention | Arm Label: Psycho-educational website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psycho-educational website | Intervention Type: BEHAVIORAL; Name: Online intervention; Assigned to Arm(s): Online intervention | Intervention Type: BEHAVIORAL; Name: Psycho-educational website; Assigned to Arm(s): Psycho-educational website
B: Arm Label: CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD | Arm Label: Imagery Rehearsal Therapy + CBT for PTSD; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD, Behavioral: Imagery Rehearsal Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for PTSD; Assigned to Arm(s): CBT for PTSD, Imagery Rehearsal Therapy + CBT for PTSD | Intervention Type: BEHAVIORAL; Name: Imagery Rehearsal Therapy; Assigned to Arm(s): Imagery Rehearsal Therapy + CBT for PTSD
C: Arm Label: PPRS video; Type: EXPERIMENTAL; Interventions: Behavioral: PPRS | Arm Label: PIRI video; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PIRI | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PPRS; Assigned to Arm(s): PPRS video | Intervention Type: BEHAVIORAL; Name: PIRI; Assigned to Arm(s): PIRI video
D: Arm Label: Brief Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy | Arm Label: Assessed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Contact Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy; Assigned to Arm(s): Brief Intervention Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Combined Anodal TDCS and Peripheral Nerve Stimulation on Motor Recovery in Acute Stroke
Brief Summary: Recent work showed that application of peripheral nerve and cortical stimulation independently can induce 10-15 % improvement in motor performance in patients with chronic stroke.

The purpose of this study was to compare in post-stroke hemiplegic patients the effect on motor recovery of one session of anodal transcranial direct current stimulation to the ipsilesional primary motor cortex (M1) combined with a peripheral radial nerve electrical stimulation (rEPNS) to the paretic hand repeated 5 successive days with the effect of the same peripheral nerve stimulation combined with sham tDCS.

Design: randomized, double-blind, parallel controlled clinical trial. Patients eligible for the study: Acute ischaemic stroke Primary outcome measure: Jebsen Taylor test Secondary outcome measures Nine peg hole test Hand tapping grip and wrist force Cortical excitability of Ipsilesional M1(TMS) Follow-up: 30 days


Options:
A: Arm Label: Real; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Arm Label: sham; Type: PLACEBO_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Intervention Type: DEVICE; Name: transcranial direct current stimulation tDCS; Assigned to Arm(s): Real, sham | Intervention Type: DEVICE; Name: transcranial magnetic stimulation TMS; Assigned to Arm(s): Real, sham
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Intervention Type: DEVICE; Name: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 2
C: Intervention Type: OTHER; Name: Visumotor Upper Extremity Training; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Anodal/Sham tDCS; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: combined transcranial direct current stimulation and electrical peripheral nerve stimulation; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Combined Anodal TDCS and Peripheral Nerve Stimulation on Motor Recovery in Acute Stroke
Brief Summary: Recent work showed that application of peripheral nerve and cortical stimulation independently can induce 10-15 % improvement in motor performance in patients with chronic stroke.

The purpose of this study was to compare in post-stroke hemiplegic patients the effect on motor recovery of one session of anodal transcranial direct current stimulation to the ipsilesional primary motor cortex (M1) combined with a peripheral radial nerve electrical stimulation (rEPNS) to the paretic hand repeated 5 successive days with the effect of the same peripheral nerve stimulation combined with sham tDCS.

Design: randomized, double-blind, parallel controlled clinical trial. Patients eligible for the study: Acute ischaemic stroke Primary outcome measure: Jebsen Taylor test Secondary outcome measures Nine peg hole test Hand tapping grip and wrist force Cortical excitability of Ipsilesional M1(TMS) Follow-up: 30 days


Options:
A: Intervention Type: DEVICE; Name: combined transcranial direct current stimulation and electrical peripheral nerve stimulation; Assigned to Arm(s): N/A
B: Arm Label: Sham tDCS and motor training: sham comparator; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Arm Label: Anodal tDCS and motor training: experimental; Type: EXPERIMENTAL; Interventions: Device: anodal tDCS (device) Eldith DC-Stimulator | Intervention Type: DEVICE; Name: anodal tDCS (device) Eldith DC-Stimulator; Assigned to Arm(s): Anodal tDCS and motor training: experimental | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS and motor training: sham comparator
C: Arm Label: Anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: DC-Stimulator to apply tDCS | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: DC-Stimulator to apply Sham tDCS | Intervention Type: DEVICE; Name: DC-Stimulator to apply tDCS; Assigned to Arm(s): Anodal tDCS | Intervention Type: DEVICE; Name: DC-Stimulator to apply Sham tDCS; Assigned to Arm(s): Sham tDCS
D: Arm Label: Action Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Action Training | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation | Arm Label: Action Training + tDCs; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation, Other: Action Training | Arm Label: Control training; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: OTHER; Name: Transcranial direct current stimulation; Assigned to Arm(s): Action Training + tDCs, tDCS | Intervention Type: OTHER; Name: Action Training; Assigned to Arm(s): Action Training, Action Training + tDCs

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Type 2 Diabetes Secondary Prevention Trial at the Reunion Island
Brief Summary: Three hundred and ninety height diabetic patients were educated during a week of hospitalisation (nutritional and physical-activity advices). After that, they were randomized in two groups : frequent follow-up (each three month) by educational nurses and dieteticians, versus no follow-up (control group). All patients were evaluated one year after their inclusion,by HbA1c (primary outcome), anthropometry, other cardiovascular risk factors, nutritionnal and physical-activity behaviours.


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A
B: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
C: Arm Label: close follow-up by nurse; Type: N/A; Interventions: Behavioral: Secondary prevention intervention trial | Arm Label: standard follow up; Type: N/A; Interventions: Behavioral: standard follow up | Intervention Type: BEHAVIORAL; Name: Secondary prevention intervention trial; Assigned to Arm(s): close follow-up by nurse | Intervention Type: BEHAVIORAL; Name: standard follow up; Assigned to Arm(s): standard follow up
D: Arm Label: Pt. 1 Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Arm Label: Pt. 1 Supportive Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Pt. 1 Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): Pt. 1 Supportive Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
Brief Summary: The purpose of this study is to determine whether milnacipran reduces widespread, non-joint pain in patients with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that milnacipran improves widespread, non-joint pain. The investigators will also use data from the trial to determine whether response to milnacipran is associated with pain-modulating mechanisms from the central nervous system. The investigators hypothesize that response to milnacipran will be greater among patients with impaired central pain mechanisms than among patients with intact central pain modulating mechanisms.


Options:
A: Arm Label: Nortriptyline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nortriptyline Hydrochloride | Arm Label: Placebo (for nortriptyline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for nortriptyline) | Intervention Type: DRUG; Name: Nortriptyline Hydrochloride; Assigned to Arm(s): Nortriptyline | Intervention Type: DRUG; Name: Placebo (for nortriptyline); Assigned to Arm(s): Placebo (for nortriptyline)
B: Arm Label: Milnacipran then placebo; Type: OTHER; Interventions: Drug: Milnacipran, Drug: Placebo | Arm Label: Placebo then milnacipran; Type: OTHER; Interventions: Drug: Milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran then placebo, Placebo then milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Milnacipran then placebo, Placebo then milnacipran
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 4; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin
Brief Summary: Approximately 60,000 premature infants are born each year who weigh less than 1,500 grams,many of whom sustain brain damage because of their prematurity. This study is designed to evaluate the long-term developmental effects of one promising neuroprotective treatment,erythropoietin (Epo), when given in the neonatal period. Using detailed neurodevelopmental testing and state-of-the-art brain imaging, we hope to determine whether this is an effective treatment to prevent brain injury associated with prematurity, and to lay the groundwork for further studies to improve the developmental outcome of infants delivered prematurely.


Options:
A: Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control
B: Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A
C: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
D: Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin
Brief Summary: Approximately 60,000 premature infants are born each year who weigh less than 1,500 grams,many of whom sustain brain damage because of their prematurity. This study is designed to evaluate the long-term developmental effects of one promising neuroprotective treatment,erythropoietin (Epo), when given in the neonatal period. Using detailed neurodevelopmental testing and state-of-the-art brain imaging, we hope to determine whether this is an effective treatment to prevent brain injury associated with prematurity, and to lay the groundwork for further studies to improve the developmental outcome of infants delivered prematurely.


Options:
A: Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
C: Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: rh G-CSF | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: rh EPO | Arm Label: G-CSF and EPO; Type: EXPERIMENTAL; Interventions: Drug: recombinant human G-CSF, and rhEPO, Drug: rh G-GSF and rh EPO together | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: recombinant human G-CSF, and rhEPO; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: rh G-CSF; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: rh EPO; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: rh G-GSF and rh EPO together; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: HLX03 group; Type: EXPERIMENTAL; Interventions: Drug: HLX03 | Arm Label: adalimumab group; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: HLX03; Assigned to Arm(s): HLX03 group | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): adalimumab group
B: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
D: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Brief Summary: This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2
B: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
C: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control

Answer: C